Furthermore, recent clinical population studies have shown that even breast tumors in the lowest risk category (ER+, early stage, small tumor size, node-negativity) and despite adjuvant treatment can have relatively high relapse rates [82], [83]. This evidence concerns the gene ESR1 and breast neoplasm.